Glucagon-like peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: a Systematic Review and Meta-analysis
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for glycemic control or weight management in patients with type 2 diabetes mellitus (T2DM) or overweight/obesity. However, there are concerns regarding their association with serious gastrointestinal adverse events though findings have been inconsistent.
